Publications in collaboration with researchers from Heidelberg University (77)

2023

  1. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188

  2. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 64, Núm. 4

  3. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer

    The European respiratory journal, Vol. 62, Núm. 4

  4. Editorial - Cell mechanics and mechanobiology

    European Journal of Cell Biology

  5. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

    Hematological Oncology, Vol. 41, Núm. 4, pp. 631-643

  6. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  7. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  8. Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party

    Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4

2022

  1. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

    Blood Cancer Journal, Vol. 12, Núm. 9

  2. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Blood, Vol. 140, Núm. 21, pp. 2248-2260

  3. Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT

    Bone Marrow Transplantation

2021

  1. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1413-1421

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (Leukemia, (2019), 33, 8, (1910-1922), 10.1038/s41375-019-0413-0)

    Leukemia

  2. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 745-756

2019

  1. Diagnostic and prognostic biomarkers in cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 108-122

  2. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016

    British Journal of Haematology

  3. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811

  4. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  5. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case–control approaches

    International Journal of Cancer, Vol. 144, Núm. 7, pp. 1540-1549